ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma evolution immunology

Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
The Scientist Staff | Mar 19, 2024
monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020 | 8 min read
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
dual expresser t cell immunology type 1 diabetes
The Science News that Shaped 2019
Kerry Grens | Dec 20, 2019 | 6 min read
A T cell discovery, “hachimoji” DNA, a new species of human, and mounting fears of espionage rounded off the list this year.
Week in Review, June 17–21
Jef Akst | Jun 21, 2013 | 4 min read
On the gene patent decision; a high-res human brain model; bats’ influence on moths mating calls; toxicants threaten brain health; platelet-driven immunity
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
How Cancers Evolve Drug Resistance
Anna Azvolinsky | Apr 1, 2017 | 10+ min read
Researchers unravel the sophisticated ways cancers evade treatments, including immunotherapies, designed to destroy them.
Aptamers Identify Protein Signatures
Ricki Lewis | Apr 1, 2001 | 3 min read
Graphic: Leza BerardoneA technique not deemed "sexy" enough for commercialization a decade ago may finally find its niche in proteomics. SomaLogic Inc. of Boulder, Colo. is pioneering aptamers, which are modified DNA molecules that bind specific proteins in body fluid samples. Aptamers are initially selected for specific binding activities from a huge starting pool, then variants are obtained during subsequent rounds of amplification. The technology builds on the ability of aptamers to bind tena
Automated Colony Pickers Evolve
Helen Dell(hdell@the-scientist.com) | Jul 3, 2005 | 6 min read
Everyone knows that the first genome sequencing projects took years of work and represent the combined product of tens of thousands of individual fragments.

Run a Search

ADVERTISEMENT